Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.
Dipropylacetic acid (DPA), and anticonvulsant known to raise brain gamma-aminobutyric acid (GABA), was administered orally to eight patients with Huntington's disease. Both alone and in combination with high oral doses of GAGA, DPA failed to ameliorate and motor signs of this disorder. At maximum dose levels, combined DPA and GABA treatment led to an apparent increase in the central turnover of both dopamine and serotonin, as estimated by the oral probenecid-loading test. These latter observations may indicate a close functional interrelation between monoaminergic and GABAnergic neural pathways in the central nervous system of man.
D000328:Adult; D000613:Aminobutyrates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012701:Serotonin / Q000378:metabolism; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000613:Aminobutyrates; D014631:Valerates; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D004298:Dopamine